WuXi AppTec Aiming To Relist Biologics Unit In Hong Kong IPO
This article was originally published in PharmAsia News
WuXi AppTec is planning to spin out its biologics CRO/CMO unit in a Hong Kong IPO that is likely to raise at least $367m, sources have confirmed. The new funding would provide the fast-growing Wuxi Biologics subsidiary with the freedom and resources to make its own pipeline portfolio decisions.
You may also be interested in...
China’s WuXi AppTec is planning separate new stock listings for various parts of its business in both China and Hong Kong, potentially raising billions of dollars in the wake of an earlier go-private transaction.
Continuing with a double-digit growth rate, China remained a leading driver for Sanofi’s global business in the fourth quarter. Going digital and building local partnerships emerged as key themes for Sanofi China to explore more opportunities, although it may face testing problems for its vaccine business in the country.
Oncologie acquires PS-targeting candidate bavituximab, which may help other cancer therapies in attacking tumors. BridgeBio's newest spinout will develop former Novartis cancer candidate infigratinib.